the real pattern in play in the OTC is almost every co.'s
the real pattern in play in the OTC is almost every co.'s stock is orchestrated
and zero doubts the dolts (SEC) know it
so what are their options .. admit publicly that when they *grandfathered* FTDs
a decade ago .. that little experiment with SROs (self regulating organizations)
was a dismal failure >> cause *reporting* was left up to those who *could* outlast *retail*?
and make *bank* .. hand over fist .. or be utilized (because they are all for hire)
by others .. who also understood how to *outlast* by any means necessary
gee i doubt that would come as much of a shock to *aware retail and OTC mgmt teams*
and with all those lovely *implosions* >> PENSON/KNIGHT .. and *glitches*
since *grandfathering* FTDs
it's clear *change* will come about with glacial movement out of the dolts
which is why .. only those *mgmt* teams .. who can *outlast* will *imo* succeed
because they will only remove a layer of *endemic rot* with all publicly traded
stox .. being electronically tagged .. and *requiring* >> hard locates so that
stock is actually returned b4 being *reused* ..
zero doubts within the next 5 to 10 years .. the SEC (after the next several rounds of *crashes/glitches*)
eventually does implement a re-grandfathering on all FTDs ..
which is exactly what those who illegally manipulate are counting on
nothing like wiping out *accountability*
that is why it never hurts to have an aware retail investor and understand the rigged game
which imo P2O clearly does .. which is why the *efforts* since RH's install as Ceo >> re: trolls .. have become almost amusing
everyone who wanted out of P2O .. has long since *SOLD* .. JAN 2014's
*volume* comes to mind .. even with wash trading
certain aromatics within the 2nd *colluding* entity shorted *imo* offshore
and that kicked in almost immediately (threshold triggered 10 days in June 2012)
but clearly was noticeable to this chart challenged retail investor by Sept 2012
and with one exception .. dutifully documented and *stopped* out @ a price point
also *called* in advance >> Jan 2013 re: dolts settlement
that was over 2.5 years ago
what is the volume in play since Jan 2013?
4kids
Plastic2Oil, Inc. (PTOI) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
ASPCA's Shocking Report on Puppy Mill Violations In a recent analysis by the ASPCA, alarming statistics have surfaced regarding animal welfare violations at USDA-licensed commercial dog breeding facilities. The findings reveal that in a given year, substantial breaches of care standards were documented, yet no actions were taken to ensure the safety of the animals....
Continue Reading
PowerReviews Launches Comprehensive Partner Program PowerReviews, a reputable name backed by 1WorldSync, has initiated an exciting Partner Program aimed at revolutionizing the way user-generated content (UGC) is leveraged. This initiative is designed to not only boost productivity but also facilitate enhanced revenue opportunities for partners who promote its advanced...
Continue Reading
Turnspire Capital Partners pulled the trigger on acquiring GHP Group back in 2024, a move that sent shockwaves through the consumer product landscape. This was no random buy; GHP's got its fingers in the pie of outdoor living products—think patio heaters and grills—all under reputable brands like Dyna-Glo and Pleasant Hearth. GHP Group: A Heavyweight Player in Outdoor...
Continue Reading
Enhancing Precision in Semiconductor Testing In the fast-evolving world of semiconductor technology, precision and performance are critical. MPI Corporation has once again demonstrated its innovative spirit by unveiling a revolutionary 250 GHz broadband test solution. This state-of-the-art system combines the power of the TITAN™ Probes and MPI's extensive expertise in...
Continue Reading
Promising Advances in Gene Therapy Recently, Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicine, showcased groundbreaking preclinical and interim clinical results for its gene therapy product, PBFT02. This was presented at a major congress focused on gene and cell therapy. Designed specifically to target frontotemporal dementia associated with GRN...
Continue Reading